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Patients with COPD usually experience mucus hypersecretion as a result of airway inflamma-
tion and response to noxious stimuli. These in turn lead to worsening airway resistance,
impaired airflow, increased work of breathing, dyspnoea and exercise intolerance. Mucus
hypersecretion may also lead to increased exacerbations and poor health related quality of life
(HRQL). Institution based pulmonary rehabilitation programs incorporating airway clearance
techniques have been shown to improve HRQL, reduce dyspnoea and improve exercise toler-
ance but are often difficult to provide due to restricted accessibility and resource implications.
This review examines the current evidence base and best clinical practice in the area of airway
clearance. Mechanical devices such as the flutter valves, positive end expiratory pressure and
high frequency chest wall oscillation (HFCWO) may be able to provide the benefits of improved
airway clearance in the patient’s home potentially with reduced demands on healthcare
resources.
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Chronic obstructive pulmonary disease (COPD) is charac-
terized by chronic obstruction of expiratory flow affecting
peripheral airways, associated with chronic bronchitis
(mucus hypersecretion with goblet cell and submucosal
gland hyperplasia) and emphysema (destruction of pulmo-
nary parenchyma), together with fibrosis and tissue
damage, and inflammation of the small airways.1 In 1959,
Fletcher hypothesized that recurrent respiratory infections
might lead to chronic bronchitis and the chronic mucus
production caused by this might lead to chronic airway
obstruction. When this hypothesis was tested, a causal
relationship between respiratory infections and sputum
production was not found and it was concluded that
smoking caused both chronic bronchitis and COPD, but the
two did not have a causal relationship.2 However, more
recent study has demonstrated that among smokers chronic
sputum production3 and increased airway bacterial counts
may be associated with a more rapid decline in lung
function.4,5
Pathophysiology
Mechanisms of airway mucus production
Cigarette smoke results in increased numbers of goblet
cells in the small airways.6 A wide variety of stimuli (e.g.,
bacteria, viruses, allergens, cigarette smoke, foreignbodies, reactive oxygen species, various cytokines, and
activated leukocytes) cause goblet cell precursors to
differentiate into mucin-producing goblet cells via activa-
tion of an epidermal growth factor receptor (EGFR)
cascade.7 Neutrophil elastase and cell surface adhesion
molecules have been implicated in the process by which
neutrophils stimulate the production of mucus from goblet
cells.8
Methods of clearance of airway mucus
Airway secretions are cleared by mucociliary clearance
(MCC), in addition to other mechanisms such as cough,
peristalsis, two-phase gaseliquid flow and alveolar clear-
ance. MCC comprises the cephalad movement of mucus
caused by the cilia lining the conducting airways which is
determined by the structure, number, movement and co-
ordination as well as the amount, composition and rheolog-
ical properties of the periciliary and mucus layers.9 MCC is
a vital mechanism of lung defence, enabling efficient
clearance of inhaled particles, including microorganisms,
from the respiratory tract.10,11 Inherited defects in ciliary
motility as well as the effects of neutrophil products may
impair ciliary beating Table 1.12
Effects of mucus hypersecretion and retention
Chronic mucus hypersecretion is significantly and consis-
tently associated with both an excess FEV1 decline and an
Table 1 Modalities and mechanisms of mucociliary clearance.
Modalities Agents Mechanisms
Mucolytics Carbocisteine Breaking down mucus strands and increased fluidity;
destabilization of chemical structure of disulfide bonds;
hydrolysation of DNA molecules and DNA length
Erdosteine
N acetyl cysteine
DNase
Gelsolin
Dextran
LMW heparin
Expectorants Guaifenesin Clearance of large airways, unlikely to be of any
clinical benefit
Mucoactive Bronchodilators Increased mucus clearance through improved
ciliary movement, reducing airway obstruction
Mucus reduction Erdosteine Reducing inflammation and mucus production
Anticholinergics
Indomethacin (NSAIDs)
Corticosteroids
Macrolide antibiotics
Non-specific Airway humidification Increasing airway humidity and water content of mucus;
unlikely to be of any clinical benefit
Aerobic exercise Shear stress improves mucus mobility and opening of
smaller airways; unlikely to be of any clinical benefit
Conventional chest
physiotherapy
Percussion and shear stresses with aids to mobilization
Mucociliary
clearance
Chest physiotherapy
(autogenic drainage,
active cycle breathing)
Effective clearance of smaller, peripheral airways
Resistive measures
Flutter valve
Positive end expiratory pressure
High frequency chest wall oscillation
Osmolar agents Mannitol Increasing mucosal water content, reducing viscosity
Amiloride
Hypertonic saline
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COPD.3 Excess mucus in the airways causes severe cough
and discomfort, and can lead to further obstruction and
inflammation.8 Hogg et al. reported that the increase in
peripheral airway wall thickness and volume of inflamma-
tory cells in the mucous exudate were directly predictive of
the stage of advancement of COPD, based on a study of
surgically resected lung tissue.13 The airways of patients
with COPD are often found to be colonized by bacteria, and
it is now recognized that higher airway bacterial loads are
associated with increased airway inflammation14 more
frequent exacerbation15 and faster lung function decline16
in smokers.17 In addition, severe airflow limitation is asso-
ciated with an increased number of neutrophils, macro-
phages, NK lymphocytes, and MIP-1aþ epithelial cells in the
bronchial mucosa.18 Airway infections and ciliary dysfunc-
tion can lead to impaired mucus transport and can thereby
increase the retention of particles, including microorgan-
isms in the airways.19,20 Hence techniques of efficient
clearance of peripheral airways may reduce airway occlu-
sion by excess mucus and inflammatory cells, improving
lung function, exercise capacity and reducing exacerbation
frequency.Therapeutic approaches to airway mucus
hypersecretion and retention
Non-pharmacological
Air humidification
Although cold air and mist humidification are commonly
used, they have been shown not to be useful in achieving
adequate air humidification nor in aiding sputum clear-
ance. There is, in fact, a higher risk of bacterial infec-
tion with mist humidification systems.21 Warm air
humidification may help in intubated patients but does
not help to improve airway clearance in non-intubated
adults.22
Exercise
Aerobic exercise leads to more rapid and deep breathing
leading to shearing force along the airway walls hence
improving clearance of secretions but although exercise
may improve functional capacity, it has not been shown to
be a replacement for physiotherapy in adequate airway
clearance in cystic fibrosis (CF).23
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Although CCPT is still considered the gold standard of
treatment in clinical practice, a Cochrane review in 2000
concluded that the evidence for this was not robust.24 This
is possibly due to a lack of appropriate trials rather than
any evidence of lack of benefit. A systematic review carried
out in 2004 to look at airway clearance techniques in all
disorders of airway clearance to produce American College
of Chest Physicians (ACCP) guidelines, found that although
some techniques improved sputum expectoration, there
was no high quality evidence for long term outcomes with
these techniques.25 They recommended the use of CCPT in
CF but noted that manually assisted cough might be detri-
mental in COPD and recommended that this technique not
be used in these patients. CCPT requires active intervention
from a trained assistant or therapist.
ACBT
The active cycle breathing technique (ACBT) is a cycle of
breathing control, thoracic expansion exercises and forced
expiration techniques (one or two huffs combined with
periods of breathing control). Huffing to low lung volumes
helps to clear the secretions from peripheral airways and
when they reach the more proximal airways, a huff or
cough from a high lung volume can be used to clear them.26
This technique has been recommended for both CF and
COPD in the ACCP guidelines for airway clearance thera-
pies.25 Various other techniques have been used as adjuncts
to ‘‘standard’’ physiotherapy for patients with CF. Forced
expiration27 and inspiration against resistance have
demonstrated better sputum expectoration than standard
therapy.28
Autogenic drainage
Autogenic drainage is the use of exhalation at different lung
volumes e from low lung volume to high lung volume e to
gradually mobilize the airway secretions from the periph-
eral to the proximal airways. It has been shown to have at
least equal efficacy to ACBT in a cohort of 30 patients with
COPD.29
Resistive inspiratory manoeuvres (RIM)
Inspiration against a fixed inspiratory resistance is thought
to improve sputum clearance. RIM was shown in CF to
improve sputum expectoration compared to standard
physiotherapy alone.28 There are no studies looking at this
technique in COPD.
Flutter
This is a pipe-shaped device with a high density stainless
steel ball-bearing enclosed in a cone in the bowl of the
‘‘pipe’’. During expiration through the flutter device, the
rise and fall of the ball and its movement along the surface
of the cone creates a positive expiratory pressure and
oscillatory vibration of the air within the airways. This
phenomenon helps to loosen secretions, which are mobi-
lized to the central airways and cleared by deep exhala-
tions through the device with the aid of subsequent
coughing and/or huffing. It has been shown that oral high
frequency oscillation improves mucociliary clearance in
normal individuals.30 A flutter device was compared to
standard chest physiotherapy in CF patients and found tobe equivalent in its effects on spirometry, 6 min walk
distance and oxygen saturations.31 However, another study
using the VRP1 flutter device, was found to be less efficient
than ACB techniques at clearing the airway and concerns
were raised about sputum retention with this device.32
There is little evidence for improved airway clearance with
the flutter device in patients with COPD, but one study of
23 patients with COPD found that the bronchodilator
response to salbutamol and ipratropium was improved after
the use of a flutter device.33
Positive expiratory pressure (PEP)
The PEP device consists of a face mask or mouthpiece and
a one-way valve to which expiratory resistors can be
attached. A manometer is inserted into the system
between the valve and the resistance to monitor the
pressure. This should be 10e20 cmH2O at mid-expiration.
Tidal breathing, with a slightly active expiration, is used
and the lung volume is retained at a higher level than the
usual residual volume by avoiding complete expiration.26 A
Cochrane review of the use of PEP devices for CF patients
concluded that there was no objective evidence that PEP
devices were either better or worse than other airway
clearance techniques. Some patients reported a preference
for PEP over standard therapy, but these studies were not
of very high quality.34 The ACCP guidelines25 have recom-
mended the use of PEP in CF because it is approximately as
effective as CCPT, is safe and can be self-administered.
However, there is no evidence available on the use of PEP
to aid sputum expectoration in COPD.
HFCWO
High frequency chest wall oscillation devices allow positive
pressure air pulses to be applied to the chest wall, for
example by means of an inflatable vest. It was hypothe-
sized that chest wall oscillation might increase the expi-
ratory flow bias and this would lead to increased mucus
clearance.35 Chest wall oscillation at 13 Hz using an inflat-
able cuff around the lower thorax was demonstrated in
early canine studies to improve tracheal mucus clearance
more effectively than in the control group or in subjects
given high frequency oscillation at the airway opening.36,37
Following this, it was recognized that the use of
a mechanical chest wall oscillatory device might be more
convenient for patients as they would be able to perform
their airway secretion clearance manoeuvers at home and
this would in turn improve compliance and efficacy.38 Most
studies of HFCWO have been performed in patients with
cystic fibrosis (CF). Darbee et al. used a protocol using
a chest wall oscillation frequency of 10 Hz for 15 min and
15 Hz for another 15 min as six cycles of 5 min of treatment
followed by expiratory and expectoration manoeuvres. This
was compared to positive expiratory pressure (PEP)
breathing at 10e20 cmH2O. Nebulized salbutamol and
normal saline were administered in both arms. FEV1 and
FVC improved with both treatments. Ventilation was more
uniformly distributed throughout the lungs and inspired
gases were better mixed with existing pulmonary gases
after both treatments. However, the oxygen saturation fell
slightly lower during treatment with HFCWO.39 Perry et al.
showed that the addition of PEEP to HFCWO at 10 Hz with
a mean chest wall pressure of 16 cm of water increased end
500 A. Bhowmik et al.expiratory lung volume and mean oscillatory flow rates
during inspiration and expiration in patients with COPD.
They therefore suggest that PEEP should be used in
conjunction with HFCWO to maximize the sputum clear-
ance obtainable with this technique.40 HFCWO has been
used in other disease conditions to attempt the improve-
ment of clearance of airway secretions. Chaisson et al.
found no benefit in FVC, oxygenation or adverse events
with HFCWO in addition to BIPAP compared with BIPAP
alone with standard therapy in patients with amyotrophic
lateral sclerosis, but there were only nine subjects.41 An
instrument to measure satisfaction levels and patient rated
efficacy levels was validated by Oermann et al. This showed
that conventional physiotherapy techniques (postural
drainage, percussion and vibration) seemed to be consid-
ered by patients with cystic fibrosis to be less efficacious
than HFCWO and less comfortable or convenient than
flutter devices. They also observed that greater satisfaction
was associated with greater compliance with therapy.42
There are no satisfactory studies to demonstrate the effect
of HFCWO on exacerbations and quality of life in patients
with COPD.
Pharmacological
Reduced airway surface liquid volume has been shown to be
an important predictor of mucosal stasis and hence effi-
ciency of mucociliary clearance. Studies in CF patients have
demonstrated clearly the disease progression when this is
impaired severely due to impaired CF transmembrane
regulator (CFTR) gene expression. Recent studies from
patients with COPD and asthma have shown that airway
surface liquid volume homeostasis is linked to activation of
adenosine receptor (A2B).43 Therapeutic strategies that
increase airway surface liquid content through osmosis may
improve hydration and hence efficiency of mucociliary
clearance. The mucus factors that favour mucociliary
transport (e.g., thin mucus gel layer, ‘‘ideal’’ sol depth,
and elasticity greater than viscosity) are opposite to those
that favour cough effectiveness (thick mucus layer, exces-
sive sol height, and viscosity greater than elasticity), which
indicates that different mucoactive drugs are likely to be
required for treatment of mucus obstruction in proximal
versus distal airways, or in patients with an impaired cough
reflex.44
Hypertonic saline
A significant inhibition of luminal sodium conductance has
been shown as a result of high luminal sodium concentra-
tions. This mechanism may be involved in the regulation of
fluid transport across the respiratory epithelium and in the
improvement of mucociliary clearance with inhalation of
hypertonic saline.45 Of the various agents that are currently
in favour, hypertonic saline has probably the maximum
interest amongst researchers in COPD (with mucus hyper-
secretion). Saline (1.21 M) was used in 1978 to demonstrate
more rapid clearance of secretions in patients with COPD.46
Hypertonic saline has been demonstrated to improve
sputum expectoration in CF in a dose dependent way,
improving with increasing concentrations of saline within
a range of 0.9e12%.47 Daviskas et al. demonstrated
increased mucociliary clearance in asthmatics and normalcontrols using 14.4% hypertonic saline, but there was a fall
in FEV1 of 22% in the asthmatic group.
48 However, the
technique of sputum induction using 3% saline has been
shown to be safe in patients with COPD suggesting that
lower concentrations of saline may have a role in improving
mucociliary clearance in these patients.49
Mannitol
As mannitol is thought to have a similar osmotic effect to
hypertonic saline, inhalation of dry powder mannitol via an
inhaler has been used to improve sputum expectoration in
asthmatics as well as healthy volunteers.50 Similar results
were obtained in bronchiectasis.51 But again, there was
a significant fall in FEV1 in the asthmatic patients of 22  3%
raising the possibility of similar falls in COPD, which might
be unsafe.
Amiloride
Amiloride has been shown to improve sputum clearance,
but is not currently recommended for clinical use.52
Mucolytics
While an early study of S-carboxymethylcysteine in patients
with chronic bronchitis found no benefit on sputum
expectoration,53 subsequent work has demonstrated
reduced sputum viscosity and increased mucociliary trans-
port after a short treatment.54 A recent study in Chinese
patients with COPD showed a reduction in frequency of
exacerbations in patients treated with Carbocysteine.55
Erdosteine has been found in animal studies to have several
possible mechanisms of action as an expectorant.56 It has
been shown to improve sputum clearance in elderly
patients with bronchiectasis and chronic mucus hyperse-
cretion.57 A study of 8 months of daily erdosteine improved
exacerbation and hospitalization rates and quality of life
scores.58 Overall, mucolytics have been shown to slightly
reduce the frequency of exacerbations and the total
number of days of disability.59 Although these drugs fell out
of favour in the UK for many years, the NICE guidelines for
the management of COPD have recommended their use in
selected patients.60
Conclusions
Many techniques have been used to aid sputum expecto-
ration and improve mucociliary clearance in patients with
a variety of chronic mucus hypersecretory conditions. The
majority of literature deals with cystic fibrosis. Novel
therapies in development are targeted at correcting the ion
transport deficiency of CF. The goal is to hydrate airway
surfaces by stimulating secretion (through activation of the
CFTR and calcium-activated chloride channels),61 and/or
inhibiting absorption (through the epithelial sodium
channel)62 thereby stimulating healthy mucociliary
clearance.63
However, these novel techniques are likely to take
sometime before reaching the realms of clinical practice.
As of now there is only limited evidence to show that some
of the techniques described have been used with benefit in
patients with COPD. Further study is required in this group
of patients as the number of people suffering from COPD is
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portion of healthcare resources. We propose that HFCWO is
a technique of self-managed efficient clearance of
peripheral airways that should be studied in patients with
COPD because there is some good evidence showing its
benefits in airway clearance in cystic fibrosis and compared
with other approaches such as hypertonic saline, erdos-
teine and NAC. This is important as many patients with
COPD have restricted mobility and may find it difficult to
attend physiotherapy sessions on a regular basis.
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